These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 32146134)

  • 1. Evaluation of naloxone access, pricing, and barriers to dispensing in Tennessee retail community pharmacies.
    Spivey CA; Wilder A; Chisholm-Burns MA; Stallworth S; Wheeler J
    J Am Pharm Assoc (2003); 2020; 60(5):694-701.e1. PubMed ID: 32146134
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preparing pharmacists to increase naloxone dispensing within community pharmacies under the Pennsylvania standing order.
    Santa HM; Amirova SG; Ventricelli DJ; Downs GE; Nowalk AA; Pringle JL; Aruru M
    Am J Health Syst Pharm; 2021 Feb; 78(4):327-335. PubMed ID: 33336254
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identifying barriers to dispensing naloxone: A survey of community pharmacists in North Carolina.
    Rudolph SE; Branham AR; Rhodes LA; Hayes HH; Moose JS; Marciniak MW
    J Am Pharm Assoc (2003); 2018; 58(4S):S55-S58.e3. PubMed ID: 30006187
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacists' perceptions regarding feasibility, acceptability, and usefulness of student-delivered naloxone education services in community pharmacy: A mixed methods study in Alabama.
    Hohmann L; Maxson R; McDowell L
    J Am Pharm Assoc (2003); 2023; 63(6):1731-1742.e4. PubMed ID: 37619850
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacists and Naloxone: Barriers to Dispensing and Effectiveness of an Educational Outreach Program.
    Hanson KA; Smart MH; Mandava MR; Carkovic E; Aslamy M; Lee TA; Pickard AS
    J Am Pharm Assoc (2003); 2023; 63(2):608-613.e3. PubMed ID: 36631342
    [TBL] [Abstract][Full Text] [Related]  

  • 6. State laws that authorize pharmacists to prescribe naloxone are associated with increased naloxone dispensing in retail pharmacies.
    Xu J; Mukherjee S
    Drug Alcohol Depend; 2021 Oct; 227():109012. PubMed ID: 34482035
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A theoretical explanation of naloxone provision among primary care physicians and community pharmacists in Tennessee.
    Salwan A; Mathis SM; Brooks B; Hagemeier NE; Tudiver F; Foster KN; Alamian A; Pack RP
    Res Social Adm Pharm; 2024 Oct; 20(10):978-985. PubMed ID: 38981793
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of Naloxone Coprescription Laws With Naloxone Prescription Dispensing in the United States.
    Sohn M; Talbert JC; Huang Z; Lofwall MR; Freeman PR
    JAMA Netw Open; 2019 Jun; 2(6):e196215. PubMed ID: 31225895
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Attitudes and availability: A comparison of naloxone dispensing across chain and independent pharmacies in rural and urban areas in Alabama.
    Sisson ML; McMahan KB; Chichester KR; Galbraith JW; Cropsey KL
    Int J Drug Policy; 2019 Dec; 74():229-235. PubMed ID: 31698165
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vital Signs: Pharmacy-Based Naloxone Dispensing - United States, 2012-2018.
    Guy GP; Haegerich TM; Evans ME; Losby JL; Young R; Jones CM
    MMWR Morb Mortal Wkly Rep; 2019 Aug; 68(31):679-686. PubMed ID: 31393863
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of a statewide community pharmacy approach to opioid harm reduction.
    Sexton SM; Marciniak MW; Gatton O; Shelton P
    J Am Pharm Assoc (2003); 2023; 63(1):389-395.e1. PubMed ID: 36369073
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Naloxone for opioid overdose prevention: pharmacists' role in community-based practice settings.
    Bailey AM; Wermeling DP
    Ann Pharmacother; 2014 May; 48(5):601-6. PubMed ID: 24523396
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Indian Health Service pharmacists engaged in opioid safety initiatives and expanding access to naloxone.
    Duvivier H; Gustafson S; Greutman M; Jangchup T; Harden AK; Reinhard A; Warshany K
    J Am Pharm Assoc (2003); 2017; 57(2S):S135-S140. PubMed ID: 28292501
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reviewing state-mandated training requirements for naloxone-dispensing pharmacists.
    Roberts AW; Carpenter DM; Smith A; Look KA
    Res Social Adm Pharm; 2019 Feb; 15(2):222-225. PubMed ID: 29650444
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacist furnishing of naloxone in California: A follow-up analysis.
    Puzantian T; Gasper JJ; Ramirez CM
    J Am Pharm Assoc (2003); 2021; 61(5):e108-e112. PubMed ID: 34246575
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacy naloxone codispensing: A mixed methods study of practices and perspectives under a statewide standing order program.
    Pollini RA; Slocum S; Ozga JE; Joyce R; Xuan Z; Green TC; Walley AY
    J Am Pharm Assoc (2003); 2022; 62(5):1546-1554. PubMed ID: 35450833
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patient, family members and community pharmacists' views of a proposed overdose prevention intervention delivered in community pharmacies for patients prescribed high-strength opioids for chronic non-cancer pain: An explorative intervention development study.
    Mercer F; Parkes T; Foster R; Steven D; McAuley A; Baldacchino A; Steele W; Schofield J; Matheson C
    Drug Alcohol Rev; 2023 Mar; 42(3):517-526. PubMed ID: 36165733
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Naloxone Co-Dispensing with Opioids: a Cluster Randomized Pragmatic Trial.
    Binswanger IA; Rinehart D; Mueller SR; Narwaney KJ; Stowell M; Wagner N; Xu S; Hanratty R; Blum J; McVaney K; Glanz JM
    J Gen Intern Med; 2022 Aug; 37(11):2624-2633. PubMed ID: 35132556
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The evaluation of mandatory alerts on long-acting opioid prescriptions and the use of a community pharmacy naloxone protocol.
    Coffman R; Johnson A; Frede S; Pleiman M; Johnson K
    J Am Pharm Assoc (2003); 2022; 62(4S):S35-S40.e1. PubMed ID: 34930681
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Piloting an opioid callback program in community pharmacies.
    Hernandez SE; Gilson AM; Gassman M; Ford JH
    J Am Pharm Assoc (2003); 2023; 63(6):1796-1802. PubMed ID: 37574197
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.